Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 2,384.9	$ 2,913.7
Marketable securities	1,942.7	1,562.2
Accounts receivable, net	2,133.6	1,880.5
Due from anti-CD20 therapeutic programs	441.1	590.2
Inventory	952.7	804.2
Other current assets	638.8	631.0
Total current assets	8,493.8	8,381.8
Marketable securities	922.8	1,408.1
Property, plant and equipment, net	3,330.7	3,247.3
Operating lease assets	436.2	427.0
Intangible assets, net	3,383.8	3,527.4
Goodwill	5,751.0	5,757.8
Deferred tax asset	1,710.2	3,232.1
Investments and other assets	1,483.3	1,252.8
Total assets	25,511.8	27,234.3
Current liabilities:
Current portion of notes payable	0.0	1,495.8
Taxes payable	576.7	71.4
Accounts payable	383.9	530.8
Accrued expenses and other	2,486.5	2,765.8
Total current liabilities	3,447.1	4,863.8
Notes payable	7,423.8	4,459.0
Deferred tax liability	1,461.5	2,810.8
Long-term operating lease liabilities	414.8	412.7
Other long-term liabilities	1,475.4	1,348.9
Total liabilities	14,222.6	13,895.2
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	0.0	0.0
Accumulated other comprehensive loss	(181.0)	(135.2)
Retained earnings	14,466.7	16,455.4
Treasury stock, at cost	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	11,308.7	13,343.2
Noncontrolling interests	(19.5)	(4.1)
Total equity	11,289.2	13,339.1
Total liabilities and equity	$ 25,511.8	$ 27,234.3